Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.
Saved in:
| Title: | Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. |
|---|---|
| Authors: | D'Haens, Geert1 (AUTHOR), Danese, Silvio2 (AUTHOR), Panaccione, Remo3 (AUTHOR), Rubin, David T4 (AUTHOR), Peyrin-Biroulet, Laurent5,6,7 (AUTHOR), Matsuoka, Katsuyoshi8 (AUTHOR), Loftus, Edward V9 (AUTHOR), Kobayashi, Taku10 (AUTHOR), Elsharkawi, Walid11 (AUTHOR), Miceli, Rosa11 (AUTHOR), Ahmed, Samia11 (AUTHOR), Luo, Yi11 (AUTHOR), Napoli, Andrew11 (AUTHOR), Vaile, John11 (AUTHOR), Dornic, Quentin11 (AUTHOR), Patel, Aditya11 (AUTHOR), Schreiber, Stefan12 (AUTHOR) |
| Source: | Journal of Crohn's & Colitis. Jun2025, Vol. 19 Issue 6, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
